145 related articles for article (PubMed ID: 38287743)
1. Genetic testing for familial melanoma.
Primiero CA; Maas EJ; Wallingford CK; Soyer HP; McInerney-Leo AM
Ital J Dermatol Venerol; 2024 Feb; 159(1):34-42. PubMed ID: 38287743
[TBL] [Abstract][Full Text] [Related]
2. [From gene to disease; from p16 to melanoma].
Gruis NA; Bergman W
Ned Tijdschr Geneeskd; 2000 Oct; 144(44):2100-2. PubMed ID: 11103670
[TBL] [Abstract][Full Text] [Related]
3. Improvement of Genetic Testing for Cutaneous Melanoma in Countries With Low to Moderate Incidence: The Rule of 2 vs the Rule of 3.
Delaunay J; Martin L; Bressac-de Paillerets B; Duru G; Ingster O; Thomas L
JAMA Dermatol; 2017 Nov; 153(11):1122-1129. PubMed ID: 28903138
[TBL] [Abstract][Full Text] [Related]
4.
Pissa M; Helkkula T; Appelqvist F; Silander G; Borg Å; Pettersson J; Lapins J; Nielsen K; Höiom V; Helgadottir H
Acta Oncol; 2021 Jul; 60(7):888-896. PubMed ID: 33945383
[No Abstract] [Full Text] [Related]
5. [Increased knowledge on familial melanoma and the underlying genetics].
Helgadottir H; Nielsen K; Höiom V
Lakartidningen; 2017 May; 114():. PubMed ID: 28485764
[TBL] [Abstract][Full Text] [Related]
6. [Genetic counseling and DNA testing in patients with increased risks for malignant melanoma].
Itin PH; Fistarol SK
Ther Umsch; 2003 Aug; 60(8):469-72. PubMed ID: 14502854
[TBL] [Abstract][Full Text] [Related]
7. Prognosis of CDKN2A germline mutation in patients with familial melanoma: a systematic review and meta-analysis.
Taibo A; Paradela S; Suanzes-Hernández J; Balboa-Barreiro V; Amado-Bouza J; Fonseca E
Melanoma Res; 2024 Feb; 34(1):9-15. PubMed ID: 37924530
[TBL] [Abstract][Full Text] [Related]
8. Familial melanoma: a complex disorder leading to controversy on DNA testing.
de Snoo FA; Bergman W; Gruis NA
Fam Cancer; 2003; 2(2):109-16. PubMed ID: 14574160
[TBL] [Abstract][Full Text] [Related]
9. Is there a role for genetic testing in patients with melanoma?
Kefford RF; Mann GJ
Curr Opin Oncol; 2003 Mar; 15(2):157-61. PubMed ID: 12601281
[TBL] [Abstract][Full Text] [Related]
10. Early onset may predict G101W CDKN2A founder mutation carrier status in Ligurian melanoma patients.
Mantelli M; Pastorino L; Ghiorzo P; Barile M; Bruno W; Gargiulo S; Sormani MP; Gliori S; Vecchio S; Ciotti P; Sertoli MR; Queirolo P; Goldstein AM; Bianchi-Scarrà G;
Melanoma Res; 2004 Dec; 14(6):443-8. PubMed ID: 15577313
[TBL] [Abstract][Full Text] [Related]
11. Geographical variation in the penetrance of CDKN2A mutations for melanoma.
Bishop DT; Demenais F; Goldstein AM; Bergman W; Bishop JN; Bressac-de Paillerets B; Chompret A; Ghiorzo P; Gruis N; Hansson J; Harland M; Hayward N; Holland EA; Mann GJ; Mantelli M; Nancarrow D; Platz A; Tucker MA;
J Natl Cancer Inst; 2002 Jun; 94(12):894-903. PubMed ID: 12072543
[TBL] [Abstract][Full Text] [Related]
12. Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample.
Begg CB; Orlow I; Hummer AJ; Armstrong BK; Kricker A; Marrett LD; Millikan RC; Gruber SB; Anton-Culver H; Zanetti R; Gallagher RP; Dwyer T; Rebbeck TR; Mitra N; Busam K; From L; Berwick M;
J Natl Cancer Inst; 2005 Oct; 97(20):1507-15. PubMed ID: 16234564
[TBL] [Abstract][Full Text] [Related]
13. Parental preferences for CDKN2A/p16 testing of minors.
Taber JM; Aspinwall LG; Kohlmann W; Dow R; Leachman SA
Genet Med; 2010 Dec; 12(12):823-38. PubMed ID: 21045708
[TBL] [Abstract][Full Text] [Related]
14. The genetics of hereditary melanoma and nevi. 1998 update.
Greene MH
Cancer; 1999 Dec; 86(11 Suppl):2464-77. PubMed ID: 10630172
[TBL] [Abstract][Full Text] [Related]
15. CDKN2A germline mutations are not associated with poor survival in an Italian cohort of melanoma patients.
Dalmasso B; Pastorino L; Ciccarese G; Andreotti V; Grillo F; Mastracci L; Spagnolo F; Ballestrero A; Queirolo P; Bruno W; Ghiorzo P
J Am Acad Dermatol; 2019 May; 80(5):1263-1271. PubMed ID: 30274933
[TBL] [Abstract][Full Text] [Related]
16. Management of familial melanoma.
Bishop JN; Harland M; Randerson-Moor J; Bishop DT
Lancet Oncol; 2007 Jan; 8(1):46-54. PubMed ID: 17196510
[TBL] [Abstract][Full Text] [Related]
17. Low prevalence of germline CDKN2A and CDK4 mutations in patients with early-onset melanoma.
Tsao H; Zhang X; Kwitkiwski K; Finkelstein DM; Sober AJ; Haluska FG
Arch Dermatol; 2000 Sep; 136(9):1118-22. PubMed ID: 10987867
[TBL] [Abstract][Full Text] [Related]
18. Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden).
Vasen HF; Gruis NA; Frants RR; van Der Velden PA; Hille ET; Bergman W
Int J Cancer; 2000 Sep; 87(6):809-11. PubMed ID: 10956390
[TBL] [Abstract][Full Text] [Related]
19. Inherited susceptibility to several cancers but absence of linkage between dysplastic nevus syndrome and CDKN2A in a melanoma family with a mutation in the CDKN2A (P16INK4A) gene.
Puig S; Ruiz A; Castel T; Volpini V; Malvehy J; Cardellach F; Lynch M; Mascaro JM; Estivill X
Hum Genet; 1997 Dec; 101(3):359-64. PubMed ID: 9439668
[TBL] [Abstract][Full Text] [Related]
20. Characterization of Potential Melanoma Predisposition Genes in High-Risk Brazilian Patients.
Soares de Sá BC; Moredo LF; Torrezan GT; Fidalgo F; de Araújo ÉSS; Formiga MN; Duprat JP; Carraro DM
Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
